Nemaura Medical (NMRD)
(Delayed Data from OTC)
$0.08 USD
0.00 (-5.43%)
Updated Mar 27, 2024 03:50 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Nemaura Medical, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 0 | 0 | 0 |
Cost Of Goods | 2 | 0 | 0 | 0 | 0 |
Gross Profit | -1 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 8 | 5 | 5 | 4 |
Income After Depreciation & Amortization | -10 | -8 | -5 | -5 | -4 |
Non-Operating Income | 2 | 0 | -2 | 0 | 0 |
Interest Expense | 6 | 7 | 0 | 0 | 0 |
Pretax Income | -14 | -14 | -7 | -5 | -4 |
Income Taxes | 0 | 0 | 0 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -14 | -6 | -4 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -14 | -6 | -4 | -4 |
Depreciation Footnote | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -7 | -4 | -5 | -4 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -10 | -8 | -5 | -5 | -4 |
Earnings Per Share Data | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 |
---|---|---|---|---|---|
Average Shares | 24.88 | 23.38 | 22.28 | 20.81 | NA |
Diluted EPS Before Non-Recurring Items | -0.57 | -0.59 | -0.28 | -0.20 | NA |
Diluted Net EPS (GAAP) | -0.57 | -0.59 | -0.28 | -0.20 | -0.20 |
Fiscal Year end for Nemaura Medical, Inc falls in the month of March .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | NA | 1.48 | 0.00 |
Gross Profit | 0.00 | 0.00 | NA | -1.48 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 1.54 | 2.05 | 2.06 | 2.70 | 0.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.54 | -2.05 | -2.06 | -4.18 | -0.63 |
Non-Operating Income | 1.31 | 1.67 | 0.11 | 1.86 | 0.00 |
Interest Expense | 1.93 | 0.82 | 0.66 | 2.06 | 1.08 |
Pretax Income | -2.16 | -1.20 | -2.60 | -4.37 | -1.72 |
Income Taxes | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | NA | 0.00 | 0.00 |
Income From Cont. Operations | -2.16 | -1.20 | -2.60 | -4.37 | -1.72 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.16 | -1.20 | -2.60 | -4.37 | -1.72 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 28.90 | 28.90 | 28.90 | 26.02 | 24.10 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.11 | -0.09 | -0.18 | -0.07 |
Diluted Net EPS (GAAP) | -0.07 | -0.05 | -0.09 | -0.16 | -0.07 |